Logo
x

Search

Subscribe Now

eli lilly

Eli Lilly Reports P-II (ALPACA) Trial Data of Lepodisiran for Heart Diseases

Eli Lilly Reports P-II (ALPACA) Trial Data of Lepodisiran for Heart Diseases

  • March 31, 2025
Eli Lilly and Incyte Highlight P-III (BRAVE-AA-PEDS) Trial Data of Baricitinib for Alopecia Areata at AAD 2025

Eli Lilly and Incyte Highlight P-III (BRAVE-AA-PEDS) Trial Data of Baricitinib for Alopecia Areata at AAD 2025

  • March 11, 2025
Eli Lilly Acquires OLX75016 from OliX Pharmaceuticals for Metabolic-Associated Steatohepatitis

Eli Lilly Acquires OLX75016 from OliX Pharmaceuticals for Metabolic-Associated Steatohepatitis

  • February 11, 2025
Eli Lilly Reveals VIVID-2 Study Data of Omvoh to Treat Crohn's Disease

Eli Lilly Reveals VIVID-2 Study Data of Omvoh to Treat Crohn's Disease

  • February 10, 2025
Eli Lilly Receives the US FDA’s Approval for Omvoh (Mirikizumab-mrkz) to Treat Crohn's Disease (CD)

Eli Lilly Receives the US FDA’s Approval for Omvoh (Mirikizumab-mrkz) to Treat Crohn's Disease (CD)

  • January 16, 2025
Eli Lilly Inks ~2.5B Deal to Acquire Scorpion Therapeutics

Eli Lilly Inks ~2.5B Deal to Acquire Scorpion Therapeutics

  • January 14, 2025
Eli Lilly Acquires OLX75016 from OliX Pharmaceuticals for Metabolic-Associated Steatohepatitis

    Eli Lilly Acquires OLX75016 from OliX Pharmaceuticals for Metabolic-Associated Steatohepatitis

    • February 11, 2025
    Eli Lilly Reveals VIVID-2 Study Data of Omvoh to Treat Crohn

      Eli Lilly Reveals VIVID-2 Study Data of Omvoh to Treat Crohn's Disease

      • February 10, 2025
      Top 20 Biopharma M&A of 2024 by Total Deal Value

        Top 20 Biopharma M&A of 2024 by Total Deal Value

        • February 6, 2025
        Eli Lilly Receives the US FDA’s Approval for Omvoh (Mirikizumab-mrkz) to Treat Crohn

          Eli Lilly Receives the US FDA’s Approval for Omvoh (Mirikizumab-mrkz) to Treat Crohn's Disease (CD)

          • January 16, 2025
          Eli Lilly Inks ~2.5B Deal to Acquire Scorpion Therapeutics

            Eli Lilly Inks ~2.5B Deal to Acquire Scorpion Therapeutics

            • January 14, 2025
            Eli Lilly Reports the US FDA’s Approval of Zepbound (Tirzepatide) to Treat Moderate-to-Severe Obstructive Sleep Apnea in Obese Adults

              Eli Lilly Reports the US FDA’s Approval of Zepbound (Tirzepatide) to Treat Moderate-to-Severe Obstructive Sleep Apnea in Obese Adu...

              • December 23, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.